DSPE-PEG2000-Maleimide |
|
رقم الكتالوجGC69025
|
DSPE-PEG-Maleimide (MW 2000) هو مركب PEG يتألف من DSPE ومجموعات الماليميد. يمكن استخدام DSPE-PEG-Maleimide (MW 2000) لبناء الدهونية.
Products are for research use only. Not for human use. We do not sell to patients.
Sample solution is provided at 25 µL, 10mM.
DSPE-PEG2000-Maleimide, a functional phosphatide-polyethylene glycol derivative, is an ideal candidate for the development of biocompatible biomaterials and drug delivery systems[1]. DSPE-PEG2000-Maleimide can be used to prepare liposome-polycation-oligonucleotides complexes by film hydration for systemic small interfering RNA (siRNA) delivery[2]. The novel nanoparticle based on DSPE-PEG2000-Maleimide showed significantly enhanced binding affinity and luciferase gene silencing activity against EGFR-overexpressing MDA-MB-231 breast cancer cells in vitro[2]. A novel maleimide bubble consisting of 90mol% DSPC, 7mol% DSPE-PEG2000, and 3mol% DSPE-PEG2000-Maleimide was used to simulate adhesion of the target bubble, the in vitro model of adherent bubbles based on DSPE-PEG2000-Maleimide can be used to study ultrasound targeted imaging[3]. DSPE–PEG2000–iRGD was synthesized by coupling iRGD peptides to DSPE–PEG2000–maleimide, whose fabrication of the iRGD-carrying αvβ3 integrin-targeted microbubbles, this DSPE–PEG2000–maleimide-based ultrasound contrast agent is widely used for molecular imaging of tumor angiogenesis[4]. The maleimide-thiol Michael addition, Aizde-DBCO (Dibenzocyclooctyne), and TCO (trans-cycloctene)-Tetrazine click chemistry were employed to conjugate three different proteins, subunit keyhole limpet hemocyanin (sKLH), Ovalbumin (OVA), and cross-reactive material 197 (CRM197), to the surface of PLGA/lipid hybrid nanoparticles (hNPs), which are useful for developing multivalent vaccines against different pathogens. Three proteins including subunit keyhole limpet hemocyanin (sKLH), Ovalbumin (OVA) and cross-reactive material 197 (CRM197) were attached to the DSPE-PEG2000-Maleimide-based PLGA/lipid hybrid nanoparticles (hNPs) through maleimide-thiol Michael addition, Aizde-DBCO (Dibenzocyclooctyne), and TCO (trans-cycloctene)-Tetrazine click chemistry to create multivalent vaccines against various pathogens[5].
References:
[1] Kang S T, Yeh C K. A maleimide-based in-vitro model for ultrasound targeted imaging[J]. Ultrasonics sonochemistry, 2011, 18(1): 327-333.
[2] Gao J, Liu W, Xia Y, et al. The promotion of siRNA delivery to breast cancer overexpressing epidermal growth factor receptor through anti-EGFR antibody conjugation by immunoliposomes[J]. Biomaterials, 2011, 32(13): 3459-3470.
[3] Kang S T, Yeh C K. A maleimide-based in-vitro model for ultrasound targeted imaging[J]. Ultrasonics sonochemistry, 2011, 18(1): 327-333.
[4] Yan F, Xu X, Chen Y, et al. A lipopeptide-based αvβ3 integrin-targeted ultrasound contrast agent for molecular imaging of tumor angiogenesis[J]. Ultrasound in medicine & biology, 2015, 41(10): 2765-2773.
[5] Hu H, Zhang C. Conjugation of Multiple Proteins Onto the Surface of PLGA/Lipid Hybrid Nanoparticles[J]. Journal of Biomedical Materials Research Part A, 2025, 113(1): e37807.
| Cas No. | SDF | ||
| Formula | M.Wt | 2955.7 | |
| الذوبان | DMF : 50 mg/mL (16.92 mM; ultrasonic and warming and heat to 60°C) | Storage | Store at -20°C, stored under nitrogen |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 338.3 μL | 1.6916 mL | 3.3833 mL |
| 5 mM | 67.7 μL | 338.3 μL | 676.7 μL |
| 10 mM | 33.8 μL | 169.2 μL | 338.3 μL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)















